contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


dagens-aktienyheder-1405-wirtek-as-gronlandsbanken-rovsing-as-og-curasight

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Head of Sales

Jesper Thomsen

WirTek is an IT company. The company is focused on developing software and hardware solutions that affect web, mobile and integrated complete systems. Operations are held on a global level, with the largest presence in the Nordic region and Europe, where customers mainly consist of small and medium-sized business customers. WirTek was founded in 2001 and is headquartered in Aalborg.

Wirtek

Grønlandsbanken is a bank that offers financial services in Greenland. The bank mainly provides traditional services for loan financing, asset management and insurance issues, both aimed at private and corporate customers. A large part of the services are offered digitally. The company was founded in 1967 and is headquartered in Nuuk, Greenland.

Grønlandsbanken

Rovsing is a technology company. The company specializes in technical development of systems, products and software solutions for the satellite and space industry. Examples of solutions that the company develops are check-out and validation systems. In addition, related engineering services are offered. Rovsing was founded in 1992 and is headquartered in Glostrup.

Rovsing

Curasight is a Danish biotech company focusing on developing and improving the detection and treatment of cancer in a more gentle and efficient way. The company has two pipeline products that both use radionuclide (nuclear medicine) to facilitate better diagnosis and treatment of various cancer types; uTRACE use the so-called uPAR as a biomarker to diagnose the aggressiveness of cancer, and uTREAT use the uPAR as a attachment to treat the cancer.

Based on good phase 2 data that has already been collected or will be in the first half of 2022, Curasight is expected to prepare phase 3 for uTRACE later in 2022 and 2023 for the following four cancer types: prostate, brain, neuroendocrine, and head and neck cancer.

Curasight

Dagens aktienyheder med Wirtek A/S, GrønlandsBANKEN, Rovsing A/S og Curasight

Wirtek har her til morgen aflagt regnskab for Q1 2025. Oms&#xe6;tningen var p&#xe5; DKK 15,5 mio. i kvartalet svarende til et fald p&#xe5; -14% sammenlignet med Q1 2024. Den lavere oms&#xe6;tning p&#xe5;virker ogs&#xe5; selskabets EBITDA, der er p&#xe5; DKK -1,1 mio. i kvartalet (DKK 1,8 mio. i Q1 2024). Trods &#xf8;get markedsusikkerhed med udskydelser i investeringsbeslutninger ser selskabet tydelige tegn p&#xe5; fremgang i internationale markeder som USA og Holland og i selskabets Energy forretning. Wirtek fastholder dermed guidance for 2025 om en oms&#xe6;tning i intervallet DKK 70-75 mio. og EBITDA i intervallet DKK 1,0-5,0 mio. Her til eftermiddag kl. 14:30 pr&#xe6;senterer Wirteks CEO Michael Aaen resultaterne for kvartalet og de seneste nyheder. Der vil ogs&#xe5; v&#xe6;re mulighed at stille sp&#xf8;rgsm&#xe5;l. Tilmeld dig og stil dine sp&#xf8;rgsm&#xe5;l nu: https://www.inderes.dk/videos/wirtek-presentation-of-q1-2025-interim-report
Gr&#xf8;nlandsBANKEN offentliggjorde i g&#xe5;r eftermiddags sit regnskab for 1. kvartal 2025, der viser en fornuftig start p&#xe5; &#xe5;ret, om end lavere nettorenteindt&#xe6;gter og h&#xf8;jere omkostninger som ventet tr&#xe6;kker bundlinjen noget ned sammenholdt med &#xe5;ret f&#xf8;r. Gr&#xf8;nlandsBANKEN fastholder sin guidance for 2025. L&#xe6;s vores kommentar her, og tilmeld dig vores event med banken senere i dag kl. 14.00: https://www.inderes.dk/analyst-comments/gronlandsbanken-fornuftig-start-pa-aret-men-som-ventet-noget-nedgang-pa-bundlinjen
Rovsing var i g&#xe5;r eftermiddag ude med hovedresultaterne for Q3 2024/25, der d&#xe6;kker perioden 1. januar 2025 til 31. marts 2025. Trods en nedgang i oms&#xe6;tningen til DKK 7,5 mio. i kvartalet (-21% ift. Q3 2023/24) melder Rovsing om et ordreindtag p&#xe5; DKK 9,3 mio. i Q3 og DKK 23,6 mio. fra 1. januar til slutningen af april efter nye kontrakter vedr&#xf8;rende ESA EnVision-missionen med Thales Alenia Space samt en ny kommerciel kontrakt med The Exploration Company p&#xe5; uafh&#xe6;ngig softwarevalidering- og verifikation (ISVV). Selskabet fastholder guidance for 2024/25. Her til formiddag kl. 11:00 kan du m&#xf8;de og stille sp&#xf8;rgsm&#xe5;l til selskabets CEO, der vil pr&#xe6;sentere resultaterne og svare p&#xe5; sp&#xf8;rgsm&#xe5;l fra tilh&#xf8;rerne. Tilmeld dig og stil dine sp&#xf8;rgsm&#xe5;l her: https://www.inderes.dk/videos/rovsing-praesentation-af-q3-202425
Curasight video med opf&#xf8;lgning p&#xe5; kapitalforh&#xf8;jelse p&#xe5; DKK 100 mio. Selskabets ledelse besvarer de mange sp&#xf8;rgsm&#xe5;l fra deltagerne &#x2013; lyt her: https://www.inderes.dk/analyst-comments/curasight-video-med-opfolgning-pa-kapitalforhojelsen-dkk-100-mio
Disclaimer: HC Andersen Capital modtager betaling fra de n&#xe6;vnte selskaber for en digital IR abonnementsaftale.
/Jesper Thomsen, d. 14/05-2025 kl. 09:13.

Dagens aktienyheder 14/05: Wirtek A/S, GrønlandsBANKEN, Rovsing A/S og Curasight

Stay up to date